

Table S3 Treatment Rankings

Treatment	LVEF	LVEDD	LVESD	LVEDV	LVESV	LVMI	e'	E/e'	E/A	SBP	NT-pro BNP	6MWT
Placebo	1	4	3	2	3	4	3	2	3	2	2	3
GLP-1RA	2	2	1	1	1	2	4	1	2	4	1	1
DPP-4i	4	3	-	3	-	1	1	3	1	1	4	-
SGLT-2i	3	1	2	4	2	3	2	4	4	3	3	2

Note: e': early diastolic velocity; E/e': mitral inflow E velocity to tissue doppler e' ratio; E/A: early diastolic to late diastolic velocities ratio; CVD: cardiovascular disease; DPP-4i: dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonist; LVEDD: left ventricular end-diastolic diameter; LVEDV: LV end-diastolic volume; LVEF: LV ejection fraction; LVESD: LV end-systolic diameter; LVESV: LV end-systolic volume; LVMI: LV mass index; NT-pro BNP: immunoreactive amino-terminal pro-brain natriuretic peptide; SBP: systolic blood pressure; SGLT-2i: sodium glucose cotransporter type 2 inhibitor; T2DM: type 2 diabetes; 6MWT: 6-min walk test.